Form 4: Century Therapeutics CEO Granted Stock Options and Restricted Stock Units

Brent Pfeiffenberger, CEO of Century Therapeutics, received stock options and restricted stock units (RSUs) on March 7, 2024, according to a Form 4 filing with the SEC.

Summary

• Brent Pfeiffenberger, the President and CEO of Century Therapeutics, Inc., was granted 17,425 restricted stock units (RSUs) and options to purchase 104,550 shares of common stock on March 7, 2024.
• The RSUs vest 25% on March 7, 2025, and the remaining 75% vest quarterly over the following three years, contingent upon continued service.
• The stock options vest 25% on March 7, 2025, with the remaining 75% vesting in 36 equal monthly installments, also subject to continued service.
• The exercise price for the stock options is $5.32.
• Following the reported transactions, Pfeiffenberger beneficially owns 1,470,704 shares of common stock and 104,550 derivative securities.
• This Form 4 is a refiling of an original filing on March 11, 2024, which was filed under the incorrect issuer due to an administrative error.
• Pfeiffenberger has a Power of Attorney in place, effective March 11, 2024, allowing Douglas Carr and Gregory Russotti to execute Forms 3, 4, and 5 on his behalf.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The grant of stock options and RSUs is a standard practice and suggests confidence in the company's future performance. The refiling due to an administrative error is a minor negative, but not significant enough to substantially lower the sentiment.

Positives

• The grant of RSUs and stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedules for both the RSUs and stock options encourage long-term commitment from the CEO.

Risks

• The value of the RSUs and stock options is dependent on the future performance of Century Therapeutics' stock, which is subject to market risks.
• If the CEO leaves the company before the RSUs and stock options fully vest, a portion of the awards will be forfeited.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the RSUs and stock options suggest an expectation of continued service and value creation over the next three years.

Industry Context

Granting stock options and RSUs to executives is a common practice in the biotechnology industry to incentivize performance and retain talent. The specific terms of the grant, such as the vesting schedule and exercise price, are often tailored to the individual company's circumstances and strategic goals.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in the biotech industry.
• Companies like CRISPR Therapeutics and Editas Medicine also utilize stock options and RSUs as part of their executive compensation packages.
• The vesting schedules and exercise prices are generally comparable to industry norms, with vesting typically occurring over a 3-4 year period.

Stakeholder Impact

• The grant of RSUs and stock options could positively impact shareholders if the CEO's performance leads to increased company value.
• The vesting schedules incentivize the CEO to remain with the company, providing stability for employees and other stakeholders.

Key Dates